Know Cancer

or
forgot password

The Role of HER Receptor Family as Indicator of Prognosis and Drug Responsiveness in Locally Advanced Prostate Cancer


Phase 2
18 Years
75 Years
Not Enrolling
Male
Prostate Cancer

Thank you

Trial Information

The Role of HER Receptor Family as Indicator of Prognosis and Drug Responsiveness in Locally Advanced Prostate Cancer


Inclusion Criteria:



- Patients were eligible if they had histologically confirmed adenocarcinoma of the
prostate and the following high-risk features: (1) clinical stage T3a disease with
(2) Gleason sum of 7 with a predominant component of 4 (i.e., Gleason 4 + 3 = 7) or
(4) Gleason sum of 8, 9 or 10.

Exclusion Criteria:

- Prior hormonal therapy,

- Prior radiation,

- Prior investigational agents,

- Prior malignancy within the last five years or had any other serious medical or
psychiatric condition or illness that would not permit the patient to be managed
according to the protocol were excluded.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment

Outcome Measure:

PSA recurrence rate stratified according to treatment modalities

Principal Investigator

Giovanni Luca Gravina, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of L'Aquila

Authority:

Italy: Ethics Committee

Study ID:

BCLT-1236

NCT ID:

NCT00418080

Start Date:

April 2002

Completion Date:

December 2006

Related Keywords:

  • Prostate Cancer
  • Prostatic Neoplasms

Name

Location